Hospitals & U.S. Health Systems
Enterprise assurance across borders
Clinical AI assurance and governance adapted to UK and US frameworks for hospitals and large health systems.
What we provide
For UK and US enterprise buyers
Independent validation
Evaluate AI before enterprise rollout.
Governance
Oversight and monitoring documentation.
Buyer readiness
Assurance mapped to UK (DTAC) or US frameworks.
The enterprise challenge
Scale raises the stakes — and the scrutiny
Large hospitals and US health systems do not pilot quietly. A technology decision can affect thousands of clinicians and hundreds of thousands of patients across multiple sites, which means the assurance bar is correspondingly high. Enterprise buyers face a more demanding version of every risk a smaller organisation does: a model that underperforms in one subgroup becomes a system-wide equity problem, an integration gap multiplies into thousands of hours of clinician workaround, and a governance shortcut becomes a board-level exposure. Procurement, legal, security and clinical leadership all hold a veto, and each speaks a different language of risk.
Cross-border systems face an additional complication. The frameworks that govern a deployment differ by jurisdiction — the UK leans on DTAC and DCB clinical-safety standards, while US buyers work to HIPAA, business associate agreements and their own security and privacy expectations. Evidence assembled for one market rarely satisfies the other without translation. We provide that translation, mapping a single evaluation onto the assurance language each of your markets requires.
Who we work with
The committee that has to say yes
CMIOs and chief clinical officers
Accountable for clinical safety and adoption across the enterprise.
CISOs and privacy officers
Owners of security, HIPAA and data-governance obligations at scale.
Value-analysis and procurement committees
Bodies that weigh evidence, cost and deliverability before purchase.
Innovation and digital teams
Leaders piloting AI and digital tools with a mandate to prove value.
A typical enterprise engagement combines independent validation, governance and oversight documentation, and an implementation-readiness pack mapped to your procurement process. Where an enterprise rollout depends on clean data exchange across an EHR estate, our interoperability assessment de-risks integration; where you need to monitor real-world performance after go-live, our healthcare data analytics capability supports ongoing assurance. Specialist clinical input is available through our expert network.
What you receive
An assurance pack mapped to your governance
Enterprise buyers do not need another slide deck; they need evidence each accountable owner can act on. A typical engagement produces a coordinated pack rather than a single report:
- Independent validation findings — accuracy, safety and subgroup performance against representative data
- Clinical-safety documentation aligned to DCB0160 deployment safety (UK) or your local equivalent
- Security and privacy mapping — HIPAA considerations and BAAs for US buyers; DSP Toolkit and data-protection alignment for the UK
- Implementation-readiness and human-oversight checklist for go-live
- Post-deployment monitoring plan to sustain assurance at scale
- Executive readout with a clear recommendation and conditions of use
Because the evaluation is assembled once and mapped onto each market's assurance language, a multinational system can make a single technology decision and defend it consistently in every jurisdiction it operates in. See UK health system and U.S. buyer readiness for how the same evidence is framed for each market.
Answers
Frequently asked questions
Do you work with US as well as UK systems?
Yes. We adapt our evaluation and governance to your framework — DTAC for the UK, and US security/privacy expectations (including HIPAA considerations and BAAs) for US buyers. See U.S. Buyer Readiness.
What do you deliver for enterprise buyers?
Independent validation, governance documentation, and an implementation/assurance pack mapped to your procurement requirements.
How do you handle algorithmic bias and equity at enterprise scale?
Enterprise deployment magnifies the consequences of model bias across diverse patient populations. Our validation examines performance across relevant subgroups and surfaces equity risks, so your governance committee can make an informed decision rather than discovering disparities after rollout. See AI Validation & Clinical Safety.
Can you support a US system that also has UK or international operations?
Yes. For multinational systems we adapt the same core evaluation to each jurisdiction's framework — DTAC and DCB clinical safety in the UK, HIPAA and US security expectations in the US — so a single technology decision can be assured consistently across markets.
Do you support assurance after go-live, not just before purchase?
Yes. Enterprise risk does not end at the purchase order. We can help stand up post-deployment monitoring — tracking real-world performance, subgroup outcomes and safety signals — so a model that drifts or behaves unexpectedly at scale is caught early rather than discovered through incidents. Our healthcare data analytics capability supports this ongoing assurance.
Who is the assurance pack written for?
It is written to be read by the whole committee that has to approve a deployment — clinical leadership, security and privacy, and procurement — rather than a single audience. Findings are mapped to each group's requirements so the evidence answers their specific questions instead of forcing them to translate a generic report.
Deploying AI at enterprise scale?
We'll help you assure it for your market and buyers.